A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.
- DOI
- 10.1007/s11523-025-01154-4
- Published
- 2025 Jul
- Container
- Targeted oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11523-025-01154-4,
title = {A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.},
author = {Siu LL and Hong DS and Döcke WD and Tetzner R and Trautwein M and Phelps C and Willuda J and Yu XQ and Nogai H and Johnson M and Goh BC},
year = {2025},
journal = {Targeted oncology},
doi = {10.1007/s11523-025-01154-4},
url = {https://doi.org/10.1007/s11523-025-01154-4}
}RIS
TY - JOUR TI - A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. AU - Siu LL AU - Hong DS AU - Döcke WD AU - Tetzner R AU - Trautwein M AU - Phelps C AU - Willuda J AU - Yu XQ AU - Nogai H AU - Johnson M AU - Goh BC PY - 2025 JO - Targeted oncology DO - 10.1007/s11523-025-01154-4 UR - https://doi.org/10.1007/s11523-025-01154-4 ER -
APA
LL, S., DS, H., WD, D., R, T., M, T., C, P., J, W., XQ, Y., H, N., M, J., & BC, G. (2025). A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.. Targeted oncology. https://doi.org/10.1007/s11523-025-01154-4
Source records
- pubmed · retrieved 2026-09-25T17:03:51.979Z